RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
Inactivation of #CDK12 Delineates a Distinct #Immunogenic Class of Advanced #Prostate #Cancer: Cell https://t.co/HW6HEu0ZdN
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
اكتشاف نوع جديد من سرطان البروستات بخصائص بصمات جينية مختلفة وتم التعرف عليها بواسطة دراسة جينومية مكثفة....👈🏻 https://t.co/gZJwtNORhR https://t.co/1kRD6FcgWn
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
Interesting work identifying a new class of prostate cancer characterized by inactivation of CDK12, focal tandem duplications, increased neoantigen burden, and higher T cell infiltration. https://t.co/QnlUAZt56V
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT RT EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https://t.co/DRWjA9sp9K CellCellPress CellPressNews impact of CDK12 umichmedicine UMRogelCancer https://t.co/twCdlTWrxz
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @DocDellaire: Newly identified CDK12 subtype of prostate cancer that responds to immune checkpoint therapy! @AminaZoubeidi https://t.co/…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
Newly identified CDK12 subtype of prostate cancer that responds to immune checkpoint therapy! @AminaZoubeidi https://t.co/VRdVpiFgGo
RT @pknoepfler: A new type of prostate cancer https://t.co/K1RHdAfjw4
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
A new type of prostate cancer https://t.co/K1RHdAfjw4
RT @EricTopol: Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https:…
Discovery of a new type of prostate #cancer in ~7% of patients, w/ biomarker, more responsive to immune checkpoint Rx https://t.co/1iBrL1gpxh @CellCellPress @CellPressNews impact of CDK12 @umichmedicine @UMRogelCancer https://t.co/8V4ghaeC8t
Congratulations @srviswanathan (a.k.a hubs) and @GavinHa. Can't believe that AR enhancer (amplified in over 75% of castrate-resistant #prostatecancer) was hiding in plain sight all these years. @broadinstitute https://t.co/UbR1eNL7sC
RT @PCF_Science: 1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #…
1-- #PCFfunded study published in @CellCellPress @CellPressNews today identifies CDK12-loss as biomarker of distinct new #ProstateCancer subset that may be sensitive to treatment with checkpoint #immunotherapy. https://t.co/IIqwKszCjX @PCFnews https://t.co
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
RT @PCF_Science: THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prost…
THREE #PCFfunded studies published in @CellCellPress @CellPressNews today! We are so proud to have supported these #prostatecancer research teams! @PCFnews https://t.co/IIqwKszCjX https://t.co/A6UGqKuNLV https://t.co/fZxxyvU91o https://t.co/MYcRL2PcSr
@GavinHa @CellCellPress @meyersonlab @AndreasMHoff @10xgenomics @ENCODE_NIH @TakedaDavid @SU2C @PCF_Science Other interesting SV findings as well: diverse rearrangements driving AR-locus gains, chromoplexy, many complex SVs, & a CDK12-associated tandem